Investigation of bioequivalence - Scientific guideline

HumanScientific guidelines

This guidance specifies the requirements for the design, conduct, and evaluation of bioequivalence studies for immediate release dosage forms with systemic action. 

On 25 January 2025, the date of coming into effect, ICH Guideline M13A on bioequivalence for immediate-release solid oral dosage forms will supersede applicable parts of this EMA guideline related to bioequivalence study considerations and data analysis for a non-replicate study design (see Tier 1 in the ICH M13 Concept_Paper - ich.org).

Note: Appendix III of the EMA guideline is already superseded by the ICH M9 Guideline on biopharmaceutics classification system-based biowaivers.

Specific considerations to enable the practical application of ICH Guideline M13A in the European Union and the transition from the current EMA Guideline on the investigation of bioequivalence have been published and are available in the section below. 

Keywords: Bioequivalence, pharmacokinetics, biowaiver, BCS-based biowaiver, in vitro dissolution, generics

Current effective version

Document history - Revision 1 (current version)

Document history - First version

Share this page